IN2012DN01232A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01232A
IN2012DN01232A IN1232DEN2012A IN2012DN01232A IN 2012DN01232 A IN2012DN01232 A IN 2012DN01232A IN 1232DEN2012 A IN1232DEN2012 A IN 1232DEN2012A IN 2012DN01232 A IN2012DN01232 A IN 2012DN01232A
Authority
IN
India
Prior art keywords
compounds
formula
well
pharmaceutically acceptable
pharmaceutical compositions
Prior art date
Application number
Inventor
Jean Ackermann
Aurelia Conte
Werner Neidhart
Matthias Nettekoven
Stanley Wertheimer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN01232A publication Critical patent/IN2012DN01232A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein A1, A2, R1 ,R2, R3 ,R4, R5 and R6 have the significance given in claim 1.
IN1232DEN2012 2009-09-11 2010-09-07 IN2012DN01232A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170071 2009-09-11
PCT/EP2010/063078 WO2011029808A1 (en) 2009-09-11 2010-09-07 Hsl inhibitors useful in the treatment of diabetes

Publications (1)

Publication Number Publication Date
IN2012DN01232A true IN2012DN01232A (en) 2015-05-15

Family

ID=42983383

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1232DEN2012 IN2012DN01232A (en) 2009-09-11 2010-09-07

Country Status (16)

Country Link
US (1) US8258158B2 (en)
EP (1) EP2475644B1 (en)
JP (1) JP5642793B2 (en)
KR (1) KR101369551B1 (en)
CN (1) CN102498099B (en)
AR (1) AR078351A1 (en)
AU (1) AU2010294326A1 (en)
BR (1) BR112012005140A2 (en)
CA (1) CA2771452A1 (en)
ES (1) ES2445166T3 (en)
IL (1) IL217966A0 (en)
IN (1) IN2012DN01232A (en)
MX (1) MX2012002597A (en)
SG (1) SG179031A1 (en)
TW (1) TW201114744A (en)
WO (1) WO2011029808A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600739C2 (en) 2011-03-18 2016-10-27 Байер Интеллектчуал Проперти Гмбх N-(3-carbamoylphenyl)-1h-pyrazole-5-carboxamide derivatives and use thereof for combating animal pests
WO2014037327A1 (en) * 2012-09-10 2014-03-13 Boehringer Ingelheim International Gmbh N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof
WO2018104220A1 (en) * 2016-12-09 2018-06-14 Boehringer Ingelheim International Gmbh Sulfonamides as inhibitors of the uptake of extracellular citrate
GB2560713A (en) * 2017-03-20 2018-09-26 Eternygen Gmbh Inhibitor of citrate transporter
CN110003177B (en) * 2019-05-28 2021-11-19 沈阳药科大学 Benzimidazole compound containing carbamido and application thereof
CN110003176B (en) * 2019-05-28 2021-12-21 沈阳药科大学 Amide-containing benzimidazole compound and application thereof
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
WO2022130352A1 (en) * 2020-12-19 2022-06-23 Cadila Healthcare Limited Novel compounds suitable for the treatment of dyslipidemia
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3779339B2 (en) 1994-03-04 2006-05-24 三井化学株式会社 Fluorine-containing carboxylic acid ester compound, liquid crystal material, liquid crystal composition, and liquid crystal element
CA2333554A1 (en) * 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
PL369952A1 (en) 2001-11-14 2005-05-02 Schering Corporation Cannabinoid receptor ligands
BRPI0609062A2 (en) * 2005-03-03 2010-02-17 F. Hofmann-La Roche Ag pharmaceutical composition, compounds, method for the therapeutic and / or prophylactic treatment of diseases that are modulated by hydroxysteroid-11β dehydrogenase inhibitors and use of the compounds
CA2636242A1 (en) * 2006-01-30 2008-05-29 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
JP2009539937A (en) * 2006-06-16 2009-11-19 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー Pharmaceutical use of substituted piperidine carboxamides
EP1958631A1 (en) 2007-02-14 2008-08-20 AEterna Zentaris GmbH Novel triazole derivatives as ligands of G-protein coupled receptors
US8324250B2 (en) * 2009-03-19 2012-12-04 Hoffmann-La Roche Inc. Piperidine derivatives as NK3 receptor antagonists
US8329904B2 (en) * 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
US8399676B2 (en) * 2009-07-30 2013-03-19 Hoffman-La Roche Inc. Piperidine derivatives

Also Published As

Publication number Publication date
US8258158B2 (en) 2012-09-04
JP2013504533A (en) 2013-02-07
KR101369551B1 (en) 2014-03-04
CA2771452A1 (en) 2011-03-17
KR20120059617A (en) 2012-06-08
HK1169993A1 (en) 2013-02-15
SG179031A1 (en) 2012-04-27
EP2475644A1 (en) 2012-07-18
MX2012002597A (en) 2012-04-02
CN102498099B (en) 2014-10-29
WO2011029808A1 (en) 2011-03-17
TW201114744A (en) 2011-05-01
AR078351A1 (en) 2011-11-02
ES2445166T3 (en) 2014-02-28
AU2010294326A1 (en) 2012-03-08
IL217966A0 (en) 2012-03-29
JP5642793B2 (en) 2014-12-17
US20110065707A1 (en) 2011-03-17
CN102498099A (en) 2012-06-13
EP2475644B1 (en) 2014-01-08
BR112012005140A2 (en) 2016-05-03

Similar Documents

Publication Publication Date Title
IN2012DN03337A (en)
MX2010005824A (en) Aminothiazole derivatives.
IN2012DN01232A (en)
MY138941A (en) Aryl-pyridine derivatives
TW200738241A (en) Pyridazine derivatives
MX2011012017A (en) Azacyclic spiroderivatives as hsl inhibitors.
IN2012DN01233A (en)
GEP20125487B (en) Organic compounds and their use
TW200745032A (en) Novel heterobicyclic derivatives
MX2009004441A (en) Indazole derivatives useful as l-cpt1 inhibitors.
TW200626558A (en) Indazolone derivatives
UA102310C2 (en) Heterocyclic sufonamides, use thereof and pharmaceuticsl compositions
TW200738655A (en) Novel bicyclic sulfonamide derivatives
PH12013500942A1 (en) Triazolopyridine compounds
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
MX2012007536A (en) Nitrogen-containing heteroaryl derivatives.
TW200833324A (en) Sulfonamide derivatives
TW200740764A (en) Pyrazolone derivatives
MX2010009022A (en) 16 alpha, 17 alpa-acetal glucocorticosteroidal derivatives and their use.
IN2012DN00765A (en)
MX2008016426A (en) Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11b-hsd 1).
MX2010005714A (en) Pyridine compounds.
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
MX2009013501A (en) Piperidine compounds and uses thereof.
GEP201606545B (en) 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections